Pivotal phase III will require at least 300 patients and will take 2 years+ to allow for recruitment etc...therefore late 2010 means that should be completed by mid 2013 and marketing approval if all goes will then be mid/late 2014
The FDA usually require some trial centres to be in the US in any pivotal phase III study so I'm a bit surprised that they only plan a trial in Europe under EMEA
With patent expiry in 2014 orphan drug status is key in trying to extend the monopoly market period, without it CVAC is dead
- Forums
- ASX - By Stock
- patient numbers required for clinical study
Pivotal phase III will require at least 300 patients and will...
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M |
Open | High | Low | Value | Volume |
28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 297652 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.0¢ | 7500 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 267172 | 0.290 |
18 | 232142 | 0.285 |
29 | 1267072 | 0.280 |
5 | 181364 | 0.275 |
10 | 229898 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.300 | 5000 | 1 |
0.305 | 196762 | 5 |
0.310 | 57067 | 3 |
0.320 | 6090 | 1 |
0.325 | 10000 | 1 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |